Financials data is unavailable for this security.
View more
Year on year Interpace Biosciences Inc grew revenues 26.31% from 31.84m to 40.21m while net income improved from a loss of 21.96m to a gain of 802.00k.
Gross margin | 59.01% |
---|---|
Net profit margin | 7.19% |
Operating margin | 10.62% |
Return on assets | 20.72% |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Interpace Biosciences Inc fell by 1.33m. However, the company earned 3.79m from its operations for a Cash Flow Margin of 9.42%. In addition the company used 87.00k on investing activities and also paid 5.03m in financing cash flows.
Cash flow per share | 0.7777 |
---|---|
Price/Cash flow per share | 2.08 |
Book value per share | -2.85 |
---|---|
Tangible book value per share | -2.85 |
More ▼
Balance sheet in USDView more
Current ratio | 0.5342 |
---|---|
Quick ratio | 0.4695 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼